Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Mar;166(3):949-954.
doi: 10.1007/s00705-021-04956-9. Epub 2021 Jan 25.

Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study

Hany M Dabbous  1 , Sherief Abd-Elsalam  2 , Manal H El-Sayed  3 , Ahmed F Sherief  1 , Fatma F S Ebeid  3 , Mohamed Samir Abd El Ghafar  4 , Shaimaa Soliman  5 , Mohamed Elbahnasawy  6 , Rehab Badawi  7 , Mohamed Awad Tageldin  8
Affiliations
Clinical Trial

Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study

Hany M Dabbous et al. Arch Virol. 2021 Mar.

Retraction in

Abstract

No specific antiviral drugs have been approved for the treatment of COVID-19. This study aimed to evaluate the efficacy of favipiravir in treatment of COVID-19. This was a multicenter randomized controlled study including 96 patients with COVID- 19 who were randomly assigned into a chloroquine (CQ) group and a favipiravir group. None of the patients in the favipiravir group needed mechanical ventilation (p = 0.129). One patient (2.3%) in the favipiravir group and two patients (4.2%) in the CQ group died (p = 1.00). Favipiravir is a promising drug for COVID-19 that decreases the hospital stay and the need for mechanical ventilation.ClinicalTrials.gov Identifier NCT04351295.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Fig. 1
Fig. 1
Flow chart of patient inclusion in the study
See this image and copyright information in PMC

References

    1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. doi: 10.1056/NEJMoa2001017. - DOI - PMC - PubMed
    1. Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology. 2018;23(2):130–137. doi: 10.1111/resp.13196. - DOI - PMC - PubMed
    1. Cascella M, Rajnik M, Cuomo A, et al. Features, evaluation and treatment coronavirus (COVID-19) Treasure Island: StatPearls Publishing; 2012. - PubMed
    1. Yazdany J, Kim AHJ. Use of hydroxychloroquine and chloroquine during the COVID-19 pandemic: what every clinician should know. Ann Intern Med. 2020;172:754–755. doi: 10.7326/M20-1334. - DOI - PMC - PubMed
    1. Hernandez AV, Roman YM, Pasupuleti V, et al. Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review. Ann Intern Med. 2020;173(4):287–296. doi: 10.7326/M20-2496. - DOI - PubMed

Associated data

LinkOut - more resources